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(J.W. von Goethe) 
  
  
 
 
  
ABSTRACT 
 
 
 
The increasing prevalence of skin cancer results in that it will soon equal that of all other 
cancers combined. Sun exposure is a well-known risk factor for its development, but 
despite the growing public awareness of the harmful consequences of ultraviolet 
radiation, the cancer incidence continues to increase, implying that other factors might 
also have a role in promoting this disease.  
 
Data from immunosuppressed patients reveals a 100-fold increased incidence of non-
melanoma skin carcinoma (NMSC), but an infectious etiology has not been established. 
However, certain human papillomaviruses (HPVs) have previously been detected in this 
type of cancer. 
 
We applied high throughput sequencing to different skin lesions in order to assess which 
organisms were present. Most viral reads (>95%) belonged to human papillomavirus.  
 
Traditionally, viral detection was performed using PCR methods. We used degenerate 
“general” HPV primers and multiplexed novel “specific” HPV primers in order to 
amplify a broad number of HPVs by PCR. This method showed a very high sensitivity, 
but the HPV types with low similarity to the primer sequences might have escaped 
amplification. Therefore, we performed an unbiased approach based on non-PCR whole 
genome amplification, independent of sequence information, in order to detect those 
“escaping” HPV types, as well as to determine if other viruses were present in the 
samples.  
 
Overall, we identified almost 100 putative novel HPV types in total, and characterized 4 
novel HPV types (HPV 197, 200, 201 and 202). Most of the HPV types were detected in 
very few patients each, and at a very low viral load (below 0.5 copies/cell), except for 
HPV 197, which was the most commonly found virus in skin tumors (37.4% of skin 
lesions). Despite the higher sensitivity of PCR methods, the unbiased approach detected 
HPV in 37/40 condyloma acuminata that had been reported as “HPV-negative” with 
specific PCR techniques. Certain HPV types, including HPV 197, were not detected by 
PCR and only by non-PCR based methods. Therefore, more unbiased PCR-independent 
methods are needed to describe which organisms are most commonly present in skin 
lesions. 
 
The work in this thesis has expanded our knowledge of the wide genomic diversity of 
HPV on the skin, and finds that PCR-independent methods are needed to describe which 
organisms are most commonly present in skin lesions. Further studies are needed to assess 
any possible role of viral infections in skin cancer, elucidation of mechanistic effects and 
determine the direction of causality of any associations.  
 
  
SAMMANFATTNING 
 
 
 
Den ökande förekomsten av hudcancer resulterar snart i lika många fall som alla andra 
cancertyper tillsammans. Solexponering är en känd riskfaktor för utveckling av 
hudcancer, men trots allmän kännedom kring de skadliga konsekvenserna av ultraviolett 
strålning, så ökar frekvensen av sjukdomen, vilket tyder på att det även kan finnas andra 
bidragande faktorer. 
 
Sjukdomsstatistik från patienter med nedsatt immunförsvar visar en 100-faldig ökad 
frekvens av icke-melanom hudcancer, men någon bakomliggande infektion har ännu inte 
kunnat fastställas. Dock har vissa typer av humant papillomvirus (HPV) hittats i denna 
typ av cancer. 
 
Vi sekvenserade allt DNA i olika hudförändringar för att undersöka vilka 
mikroorganismer de innehöll. De flesta virussekvenserna (>95%) kom från HPV. 
 
Traditionellt har virus detekterats med olika PCR-metoder. Vi använde oss av 
degenererade ”generella” HPV-primers och multiplexade nya ”specifika” HPV-primers 
för att möjliggöra PCR-amplifiering av många olika HPV-typer. Denna metod visade på 
en mycket hög känslighet, men HPV-typer med låg likhet till primersekvenserna kan ha 
undgått amplifiering. För ett mer objektivt tillvägagångssätt amplifierade vi allt DNA utan 
PCR och oberoende av någon sekvensinformation för att kunna detektera eventuella 
HPV-typer som kan ha undgått PCR-amplifieringen likväl som andra virus i proverna. 
 
Totalt identifierade vi nära 100 möjliga nya HPV-typer, samt karaktäriserade 4 nya HPV-
typer (HPV 197, 200, 201 och 202). De flesta HPV-typerna detekterades bara i några få 
patienter var, med mycket låga virustal (mindre än 0,5 kopior/cell), förutom HPV 197, 
vilket var det vanligast förekommande viruset bland hudtumörer (37,4% av 
hudförändringarna). Trots den högre känsligheten hos PCR-baserade metoder, detekterade 
den mer objektiva PCR-oberoende metoden HPV i 37/40 condylomata acuminata som 
alla tidigare rapporterats som HPV-negativa med specifika PCR-metoder. Vissa HPV-
typer, inklusive HPV 197, detekterades inte med PCR, utan enbart med metoder utan 
PCR. Därför behövs fler objektiva, PCR-oberoende, metoder för att beskriva vilka 
mikroorganismer som är vanligast förekommande i hudförändringar. 
 
Arbetet i denna avhandling har utökat vår kunskap om den stora genetiska mångfalden av 
HPV i hud, samt konstaterar att PCR-oberoende metoder är nödvändiga för att beskriva 
vilka mikroorganismer som är vanligast förekommande i hudförändringar. Vidare studier 
är nödvändiga för att fastställa möjliga samband mellan virusinfektioner och hudcancer, 
klargöra mekanistiska effekter, samt avgöra orsaksriktning mellan funna samband. 
 
  
RESUMEN 
 
 
El cáncer de piel es el más frecuente de los cánceres en el ser humano. A pesar de que la 
exposición a la luz ultravioleta es un factor de riesgo bien conocido y de la creciente 
concienciación popular sobre sus efectos perjudiciales, la incidencia de este cáncer 
continúa aumentando. Se estima que no tardará mucho en sobrepasar en número a la suma 
del resto de cánceres. Esto sugiere que pueden existir otros factores que contribuyen al 
desarrollo de esta enfermedad. 
 
Las personas inmunodeprimidas presentan una mayor incidencia en la mayoría de los 
cánceres, sobre todo en los causados por virus oncogénicos (consecuencia de la reducción 
general de su respuesta inmune). El cáncer de piel tipo no melanoma presenta la 
incidencia más elevada (>100 veces) en este tipo de pacientes, pero aún no se ha asociado 
ningún agente etiológico que justifique esta situación.  
 
A lo largo de esta tesis, se han secuenciado (secuenciación masiva de nueva generación) 
diferentes lesiones de piel con el fin de determinar los organismos presentes en la 
epidermis. La mayoría de las secuencias virales obtenidas (>95%) correspondieron al 
virus del papiloma humano (HPV). Tradicionalmente, la detección de virus ha venido 
realizándose mediante la reacción en cadena de la polimerasa (PCR). En esta tesis se 
utilizaron múltiples pares de primers y primers degenerados con el objetivo de amplificar 
un gran número de HPVs, obteniendo una gran sensibilidad. Sin embargo, aquellos 
genotipos cuyas secuencias no fuesen similares a las secuencias de los primers, pudieron 
no haberse amplificado, y por tanto, no ser detectados. Para obviar esta limitación se optó 
por realizar un protocolo no sesgado (WGA), independiente de la secuencia a amplificar, 
para determinar si había más genotipos de HPV y/o otros virus presentes en las diferentes 
lesiones de piel.  
  
Esta tesis ha permitido identificar hasta casi 100 secuencias pertenecientes a posibles 
nuevos tipos de HPV y caracterizar 4 nuevos genotipos (HPV 197, 200, 201 and 202). La 
mayoría de los HPVs se detectaron en muy pocos pacientes cada uno y en una 
concentración viral baja (<0.5 copias/célula), a excepción del HPV 197, que fue el 
genotipo encontrado con mayor frecuencia (presente en el 37,4% de las lesiones). A pesar 
de que los métodos basados en la PCR fueron más sensibles, el método basado en WGA 
fue capaz de detectar HPV en 37/40 condilomas, que habían sido previamente 
clasificados como HPV-negativos tras genotiparse vía PCR. Algunos HPV, como el tipo 
197, fueron detectados solo con el protocolo basado en WGA. Por lo tanto, estimamos 
que son necesarios más métodos no sesgados, imparciales, para descubrir cuáles son los 
organismos presentes con mayor frecuencia en las lesiones de piel.  
 
El trabajo realizado en esta tesis ha incrementado nuestro conocimiento sobre la gran 
diversidad genómica del HPV en la piel. Se necesitan más estudios para evaluar cualquier 
posible asociación de una infección viral con el cáncer, dilucidar los mecanismos para su  
desarrollo y determinar la dirección de causalidad. 
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1 INTRODUCTION 
 
 
 
1.1 NON-MELANOMA SKIN CANCER 
 
 
The skin provides protection and receives sensory stimuli from the external environment, 
being the largest organ in the body. It is composed of three primary layers: epidermis, 
dermis and hypodermis (Figure 1).  
 
Most skin cancers arise from the epidermis and are named for the type of cells that 
become malignant. There are three major types of skin carcinoma: 
 
- Basal cell skin cancer (BCC), 
the most frequently occurring 
form of skin cancer. This 
carcinoma arises in the skin’s 
basal cells, which compose the 
deepest layer of the epidermis. 
  
- Squamous cell skin cancer 
(SCC), the second most common 
form of skin cancer. This tumor is 
an uncontrolled growth of 
abnormal cells arising in the 
squamous cells, which line most 
of the epidermis´ upper layers.  
 
- Melanoma, the most dangerous form of skin cancer. This type of cancer originates 
in the melanocytes, the pigment-producing cells located in the basal layer of the 
epidermis.  
 
 
Figure 1:   Schematic picture of a cross section 
of the skin. Image reprinted with permission 
from the National Cancer Institute, 2016. 
Illustrator: Don Bliss. 
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BCC and SCC are generally grouped together as non-melanoma skin cancers (NMSCs) to 
distinguish them from melanoma, which develops from very different cells and is treated 
differently, because it is more likely to metastasize. 
 
About 80% of all NMSC are BCCs while SCCs constitute up to 20% [1]. There are a few 
other rarer types which represent only 1% of skin cancers [1], including 
keratoacanthomas (KA) - a benign tumor, characterized by a rapid onset followed by 
spontaneous regression within a few months, Merkel cell carcinomas, cutaneous 
lymphomas, Kaposi sarcomas and skin adnexal tumors and sarcomas, all of which are 
classified as non-melanoma skin cancers.  
 
The worldwide incidence of skin cancers has been increasing over the past decades [2-4]. 
However, it is very difficult to gather overall statistics on NMSC as BCC commonly does 
not enter the cancer data collection system, since this type of skin cancer is generally 
treated successfully by dermatologists, and therefore, does not require hospitalization [2]. 
Consequently, national rates are not available for many countries and worldwide NMSC 
statistics are often estimates [2]. Most authors report that the average yearly increase in 
incidence of non-melanoma skin cancer since 1960 is about 3-8%, worldwide [5, 6]. It is 
estimated that one in every three cancers diagnosed is a skin cancer; between 2 and 3 
million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally 
each year (http://www.who.int, accessed on 2016-01-15). These data suggest that the 
prevalence of these tumors will soon equal that of all other cancers combined. 
 
In the case of Sweden, according to regulations by the Swedish National Board of Health 
and Welfare, all pathology and cytology departments in Sweden must nowadays report all 
cases of SCC and BCC (SOSFS 2006:15) to the National Swedish Cancer Register. The 
registration of SCC started already in 1958 whereas registration of BCC started in 2003 
[7]. The quality of the infrastructure of the Swedish Cancer Register in terms of 
completeness, width of information, and reliability of linkage using the personal 
identification number is internationally recognized. Nordic Registries are known to be 
very accurate with an overall completeness of over 95% (almost 100% for solid tumors) 
[8]. Data collected on NMSC in Sweden shows an increase over the past years in 
accordance with the overall estimated incidence (Figure 2, Table 1).  
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Figure 2:   Total number of new skin cancer cases (ICD-7 191. Melanoma excluded) per 100,000 
persons (crude rate) in Sweden, 1970-2013. (From the National Board of Health and Welfare´s 
statistical database, accessed on 2016-01-15). 
 
 
 
 
 
 
 
 
 
 
Table 1:   Total number of BCCs by gender, 2004-2011. (From the National Board of Health and 
Welfare´s statistical database, accessed on 2016-01-15). 
 
 
The fact that NMSC occurs mainly on sun-exposed sites and that its prevalence can be 
reduced by sun-protection, provides indirect but crucial evidence for the etiology of 
ambient solar radiation. While the role of cumulative sun exposure in SCC is well 
established, the association between sun exposure and BCC seems to rely on intermittent 
sun exposure and exposure during childhood. Even though we have identified the most 
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important risk factor and despite growing public awareness of harmful consequences of 
sun exposure, NMSC incidence continues to increase.  
 
The rising incidence of NMSC might partly be explained by increased patient and 
physician awareness of the disease, improved coding, as well as an age shift in the 
population. Furthermore, it might also suggest that other factors might have a role in 
promoting NMSC in addition to ultraviolet (UV) radiation.  
 
Several complex genotypic, phenotypic and environmental factors contribute to 
pathogenesis of NMSC. Older age, male sex, fair skin, blond hair, blue eyes, weakened or 
suppressed immune system [9-12], and a number of inherited genetic skin conditions like 
epidermodysplasia verruciformis (EV), influence cancer development 
(http://www.cancer.net, accessed on 2016-01-15).  
 
 
1.2 INFECTIONS AND NON-MELANOMA SKIN CANCER  
 
 
The last few decades have led to the realization that a considerable proportion of cancers 
develop due to infections [13]. Considering infectious agents classified by International 
Agency for Research on Cancer (IARC) as carcinogenic to humans, 2.1 million (16.4%) 
of the total 12.7 million new cancer cases that occurred in 2008 in the world were 
attributable to infections [13].  
 
To date, eight very different viruses have been identified as carcinogenic in humans, 
including retroviruses (Human T-cell leukaemia virus type I and Human 
immunodeficiency virus type I), RNA-viruses (Hepatitis C virus), DNA viruses with 
retroviral features (Hepatitis B virus), and both large double-stranded DNA viruses 
(Epstein-Barr virus and Kaposi Sarcoma-associated herpesvirus) and small double-
stranded viruses (Human papillomavirus, HPV; and Merkel Cell Polyomavirus) [14, 15]. 
In addition, a bacterium (Helicobacter pylori) and some parasites are also clearly 
implicated in human cancer [13]. 
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All oncogenic infectious agents identified so far have the ability to establish persistent 
infection in their host. The immune system controls the replication of infectious agents  
(particularly viruses) and/or expansion of infected cells. Immunosuppression is 
accompanied by a higher fraction of infection-associated cancers [11, 16-18]. 
 
Nordic, including Swedish, registry linkage studies were influential in establishing the 
large excess risk of cancer among transplant recipients more than 10 years ago [11, 19]. A 
few cancer types such as brain, breast, corpus uteri, and prostate cancers show no 
significantly increased incidence in immunosuppressed patients compared to the general 
population [15, 19]. However, majority of cancers (as well as the overall cancer 
incidence) is greatly increased among these patients [15, 19]. 
 
Most cancer types that are increased among transplant recipients are known to be caused 
by viruses, e.g. HPV-associated anogenital cancers, Epstein-Barr virus-associated 
lymphomas, Merkel cell carcinomas and HepatitisB/HepatitisC-associated liver cancers 
[18], implying that immunosuppression specifically induces an impaired ability to control 
tumorgenic viruses. 
 
As was pointed out by the 2008 Nobel Laureate Harald zur Hausen, exploration of any 
further role of infections in cancer is likely to be particularly rewarding if it is focused on 
the cancer forms that are increased among the immunosuppressed, but that do not have an 
established microbiological etiology [14]. Non-melanoma carcinoma of the skin (NMSC), 
including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), is by far the 
most highly increased disease in this patient group (about 100-fold increased incidence) 
[18], but an infectious etiology has not been established. 
 
 
1.3 POTENTIAL PATHOGENS IN SKIN CANCER 
 
 
The extreme variety of infectious agents potentially involved in human cancer rules out 
the possibility of predicting promising candidates. However, human papillomaviruses and 
bacteria (Staphylococcus aureus) have previously been detected in SCC [20-23].  
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The experiments carried out in this thesis have searched for viruses in NMSC (HPVs as 
well as other viruses). Metagenomic sequencing found that >95% of the viral sequences 
present in skin samples belonged to the Papillomaviridae family [24] and no other 
specific virus was commonly detected in most skin cancer specimens. Most studies so far 
have been carried out after using general polymerase chain reaction (PCR) systems and 
therefore, they are biased to detect only viruses with sequences of high similarity to the 
PCR primers used. Viruses that present low similarity to the primer sequences may have 
remained undetected in previous studies.  
 
 
1.3.1 HPV 
 
 
1.3.1.1 Nomenclature and classification 
 
 
The genus Papillomavirus is a group of small, non-enveloped DNA viruses known since 
antiquity but first described in the 1930’s [25]. The name “Papilloma” comes from the 
Latin term “papilla” (pustule or nipple) and the Greek suffix “oma” (tumor). 
Papillomaviruses are identified by the abbreviation PV and one or two letters indicating 
the host species. For example, human papilloma virus is identified as HPV. 
 
Papillomavirus isolates were traditionally described as “types”. The rapid increase in the 
number of isolates identified demonstrated a need for a taxonomic classification within 
the family [26]. The first attempt to classify all types relied on the ability of the viruses to 
infect the squamous epithelium (skin types) or the mucosal epithelium (mucosal types). 
However, this classification was found to be incorrect due to the possible presence of the 
same type in both types of epithelium. 
 
HPV classification and nomenclature is based on sequence analysis, as inefficient cell 
culture systems have limited the possibilities for classification based on biological 
properties. Both the ability to obtain amplification products based on the PCR technique, 
and the high stability and conservation of HPV genomes over evolution, support the 
current classification system based on the differences found in the genome [26],  
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particularly in the L1 open reading frame, which is the most conserved gene in the 
genome and encodes for the major capsid protein.  
 
Classifications are as follows (Figure 3, Table 2): 
 
- Genus: different genera within a family share less than 60% nucleotide sequence 
identity. Currently, human papillomaviruses are divided in five different genera 
(alpha, beta, gamma, mu and nu). 
- Species: different species within a genus share between 60% and 70% nucleotide 
identity. There are a total of 49 species, which are designated with a number. 
- Genotype (type): genotypes within a species share between 71 and 89% 
nucleotide homology.  
 
The International Committee on Taxonomy of Viruses is responsible for the 
papillomavirus nomenclature down to the species [26-28]. In order to establish a potential 
novel HPV type officially, the whole viral genome must be cloned (more than one 
plasmid can be used) and sent to the International HPV Reference Center together with 
the sequence. The International HPV Reference Center will confirm the DNA sequence 
and assign the submitted clones the novel HPV genotype number, if it is novel.  
 
Today, 205 HPV different genotypes have been completely cloned, sequenced and given 
an official number at the International HPV Reference Center (http://www.hpvcenter.se, 
accessed on 2016-01-15). Four previously awarded HPV type numbers (HPV46, HPV55, 
HPV64 and HPV79) were withdrawn (mostly due to re-classification as subtypes of other 
HPV types). There are therefore 201 different HPV types established today. 
 
The number of HPV types is continuously growing. The exact number of putative novel 
types is difficult to ascertain, mostly due to the possibility of different non-overlapping 
partial sequences representing the same virus type.  
 
It is estimated that at least 400 different HPV types exist [29]. In the HPV center, 360 
putatively novel HPV types have been already discovered [30-33]. The gamma genus is 
rapidly growing with now up to 81completely HPV established types, surpassing alpha 
and beta genera, with 65 and 51 types, respectively (Figure 3, Table 2).  
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During the last five-year period, 77% of all new HPVs deposited in the International 
Reference Center belonged to the gamma genus. Surprisingly, mu and nu genera have 
almost not increased in number. Methods that are independent of sequence information 
have not revealed any additional members. An exception is the recently discovered HPV 
204, isolated from the anal canal. 
 
 
Figure 3:   Phylogenetic tree of 204 HPV types. Alpha, beta, gamma, mu and nu papillomaviruses 
are presented in red, green, blue, orange and purple colors, respectively. The phylogenetic tree is 
based on the L1 part of the genome. 
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Genus  Species  First HPV type Other HPV types Date 
Alpha 
Alpha-1 HPV32 42 1986-1987 
Alpha-2 HPV3 10, 28, 29, 77, 78, 94, 117, 125, 160  1984-2009 
Alpha-3 HPV61 62, 72, 81, 83, 84, 86, 87, 89, 102, 114 1989-2008 
Alpha-4 HPV2 27, 57  1984-1989 
Alpha-5 HPV26 51, 69, 82 1985-1997 
Alpha-6 HPV30 53, 56, 66 1981-1987 
Alpha-7 HPV18 39, 45, 59, 68, 70, 85, 97 1981-2004 
Alpha-8 HPV7 40, 43, 91 1984-2001 
Alpha-9 HPV16 31, 33, 35, 52, 58, 67 1984-1989 
Alpha-10 HPV6 11, 13, 44, 74 1984-1993 
Alpha-11 HPV34 73, 177 1985-2013 
Alpha-13 HPV54 
 
1987 
Alpha-14 HPV71 90, 106 1991-2004 
Beta 
Beta-1 HPV5 
8, 12, 14, 19, 20, 21, 24, 25, 36, 47, 93, 98, 99, 
105, 118, 124, 143, 152, 195, 196 1984 - 2014 
Beta-2 HPV9 
15, 17, 22, 23, 37, 38, 80, 100, 104, 107, 110, 
111, 113, 120, 122, 145, 151, 159, 175, 182, 198 1984-2014 
Beta-3 HPV49 75, 76, 115 1987-2008 
Beta-4 HPV92 
 
2001 
Beta-5 HPV96 150, 185 2002-2013 
Gamma 
Gamma-1 HPV4 65, 95, 95, 158, 173, 205 1984-2015 
Gamma-2 HPV48 200 1987-2014 
Gamma-3 HPV50 188 19872013 
Gamma-4 HPV60 
 
1989 
Gamma-5 HPV88 
 
2001 
Gamma-6 HPV101 103, 108 2004-2006 
Gamma-7 HPV109 123, 134, 138, 139, 149, 155, 170, 186, 189, 193 2007-2014 
Gamma-8 HPV112 119, 147, 164, 168, 176 2007-2013 
Gamma-9 HPV116 129 2009 
Gamma-10 HPV121 130, 133, 142, 180, 191 2009-2013 
Gamma-11 HPV126 136, 140, 141, 154, 169, 171, 181, 202 2010-2014 
Gamma-12 HPV127 132, 148, 157, 165, 199 2009-2014 
Gamma-13 HPV128 153 2009-2011 
Gamma-14 HPV131 
 
2009 
Gamma-15 HPV135 146, 179, 192 2009-2013 
Gamma-16 HPV137 
 
2009 
Gamma-17 HPV144 
 
2010 
Gamma-18 HPV156 
 
2011 
Gamma-19 HPV161 162, 166  2012 
Gamma-20 HPV163 183, 194 2012-2014 
Gamma-21 HPV167 
 
2012 
Gamma-22a HPV172 
 
2012 
Gamma-23a HPV175 
 
2013 
Gamma-24a HPV178 190, 197 2013-2014 
 
 
10 
 
Genus  Species  First HPV type Other HPV types Date 
Gamma 
Gamma-25a HPV184 
 
2013 
Gamma-26a HPV187 
 
2013 
Gamma-27a HPV201 
 
2014 
Unclassified HPV203   2014 
Mu 
Mu-1 HPV1   1984 
Mu-2 HPV63 
 
1991 
Unclassified HPV204   2014 
Nu Nu-1 HPV41   1987 
 
Table 2:   Established HPV types, stratified by species and genera. Date refers to the period when 
HPV types were officially assigned with an established number by the International HPV 
Reference Center. a: Species assignments are tentative and not official, but recommended to the 
papilloma virus working group of  ICTV. Modified table from www.hpvcenter.se, accessed on 
2016-01-15. 
 
 
1.3.1.2 HPV in Skin Cancer 
 
 
The papillomavirus life cycle is tightly linked to the differentiation process of the infected 
epithelium. Papillomaviruses initially infect basal epithelial cells, which constitute the 
only cell layer in an epithelium that actively divides. The mechanisms by which HPV 
induces neoplastic transformation are probably various, and in fact, in vitro models 
demonstrate only a weak potential. It (neoplastic transformation) is attributed in a large 
part to the actions of the HPV E6 and E7 oncogenes [34-36]. 
 
These oncoproteins inactivate tumor suppressor genes that operate at key cell cycle 
checkpoints. E6 interferes with p53, leading to genomic instability and blocking of 
apoptosis, allowing cells with damaged DNA to replicate rather than self-destruct while 
E7 inactivates retinoblastoma signaling, leading to induction of DNA synthesis in 
keratinocytes that would otherwise be terminally differentiated and non-replicating [37]. 
 
Interestingly, SCCs derived from mice with a deletion of the retinoblastoma protein or the 
p53 gene only in skin, exhibit similar molecular signatures to that of HPV-induced 
tumors, suggesting a role of HPV in the carcinogenesis of SCC [38]. Thus, when E6 and 
E7 act synergistically, not only do they promote inhibition of apoptosis and dysregulation 
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of the cell cycle leading to abnormal cell growth, but also induce cellular genomic 
instability contributing to carcinogenesis. However, the effect by itself is not enough to 
transform cells [39].  
 
UV exposure is an important cofactor in HPV carcinogenesis. It may be then, that the 
contribution of HPV infection to cancer is via the anti-apoptotic effect in UV-damaged 
keratinocytes, which would have otherwise progressed to senescence and disintegration. 
This inhibition of apoptosis probably results in persistent viral infection and hence the 
accumulation of further DNA mutations, putatively leading to immortalized cells. 
Unrepaired DNA damage has been observed in UVB-irradiated cells expressing the E6 
protein, and inactivation of the retinoblastoma protein with HPV 16 E7 has resulted in 
significant inhibition of the ability to recover mRNA synthesis and increased levels of 
apoptosis following UV radiation [40, 41]. 
 
An association between HPV and NMSC has been found among patients with 
epidermodysplasia verruciformis (EV), a rare hereditary immunosuppressive disease [42]. 
EV patients develop skin lesions in early infanthood and present eruptions of wart-like 
lesions which are refractory to conventional wart treatment and progress to SCC at sun-
exposed sites of the skin [43]. The persistence of HPV infection in EV has been suggested 
to be due to the inability of the patient’s immune system to reject HPV-infected 
keratinocytes by a still unknown immunogenetic defect and is probably also influenced by 
environmental factors, particularly ultraviolet radiation [44]. The HPV types found in 
patients with EV are referred to as EV-HPV types, and include, among others, HPV types 
5, 8, 9, 12, 14, 15, 17, and 19–25 [45, 46]. HPV 5 and 8 are the most prevalent types [47].  
 
In contrast to cervical cancer where HPV genotypes 16 and 18 have been established as 
the most prevalent genotypes which cause this disease (70% of cancer cases) and in 
contrast to patients suffering from EV where HPV 5 and 8 are high-risk genotypes for 
skin cancer, the HPV types found in skin cancers of the general population have varied 
depending on which PCR-system was used [48, 49]. It is common to detect multiple 
genotypes in a single specimen [24, 50].  
 
Metagenomic sequencing has revealed that >95% of the viral sequences present in NMSC 
samples belong to the Papillomaviridae family, mostly to the beta and gamma genera 
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[24] but so far, only one study, that is included in this thesis, has detected a particular 
genotype (HPV 197) with high frequency (37.4%) [30] . 
 
Infections of HPV in skin are very common, but because of the diversity of HPV types, 
there does not appear to exist any single virus that is widely spread.  Acquisition appears 
to occur already shortly after birth [51-54]. A broad spectrum of cutaneous HPV is 
commonly detected both on healthy skin [55, 56], in plucked eyebrow samples [57-59] as 
well as in different skin diseases such as SCC, BCC, actinic keratosis (AK) – a precursor 
lesion for SCC – and in KAs, in both immunocompetent and immunosuppressed patients 
[60-63]. 
 
It has to be highlighted that detection of an HPV type in skin tumors does not necessarily 
mean that an HPV infection has been detected, as it may merely be a viral contamination 
of the skin surface. Forslund et al. demonstrated that cleansing of the skin by simple tape 
stripping before sampling, strongly reduces the proportion of HPV positive samples [62]. 
Prevalence dropped from 69% in swabs from top of SCCs, BCCs and AK lesions, to 12% 
in the corresponding biopsies, after cleansing the skin surface.  
 
When skin biopsies from NMSC only contain low viral loads (<1 copy/cell) [22, 64-66], 
it is debatable whether such low viral copy numbers are biologically relevant to tumor 
initiation and maintenance.  
 
 
1.4 VIRAL DETECTION IN SKIN CANCER 
 
 
When analyzing human skin specimens, one has to take into account that besides human 
DNA and RNA, human skin harbors various physiological populations of 
microorganisms, including commensal or symbiotic bacteria, fungi, parasites and viruses, 
overall known as the skin microbiota. 
 
Sequencing studies reveal that viruses represent < 1% of the total genomic material in 
skin [31] and therefore, detection of any virus by NGS, formerly required performing 
some type of viral enrichment or amplification first. Viral enrichment can be achieved by 
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performing: low-speed centrifugation and/or filtration to remove bacterial and host cells, 
nuclease treatment to digest nucleic acids that are not protected with virions [67], 
separation of long chromosomal DNA from shorter DNA [31], high-speed gradient 
centrifugation [68] or targeted sequence capture [69-71]. Each of these procedures may 
bias against detection of some viruses and result in decreased assay sensitivity as a result 
of loss of viral nucleic acids. Novel protocols designed to overcome these problems look 
very promising. ViroCap for instance, is a viral targeted sequence capture panel, with 
multiple probes designed to capture most viral species that infect vertebrates (337 viral 
species). This test is also capable to capture those viruses that share up to 58% variation 
from the reference viruses used to select capture probes [72]. 
 
The publications included in this thesis analyze only DNA virus (no RNA) and thus, 
amplification techniques and detection methods will focus on DNA. RNA viral presence 
will be discussed in the section “Concluding remarks and future perspectives”. 
 
 
1.4.1 Amplification techniques 
 
 
1.4.1.1 PCR using “general” or “degenerated” primers 
 
 
The relative ease and economic accessibility of the PCR technique made it one of the 
most widely used techniques in clinical diagnostics. Several general primer PCR systems 
targeting the L1 gene (FAP, CUT, PGMY, MGP) [33, 48, 73, 74] can amplify a broad 
range of HPV types. However, efficiency of any PCR based amplification depends on the 
number, position, and stability of mismatches between the primers and the template. The 
sequence to be amplified must be previously known and thus, amplification is biased to 
detect only sequences of high similarity to the primers used. HPV types with low 
similarity to the primer sequences will remain undetected.  
 
As an example, Forslund et al., designed PCR FAP primers from two relatively conserved 
regions of the L1 open reading frame taking into consideration most known genome 
sequences, from HPV 1 to HPV 80 [49]. FAP primers could detect 65/75 (86.7%) 
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different HPV types but were not able to amplify HPV types 1, 2, 35, 41, 44, 55, 63, 66, 
71 or 74. The failure in detecting HPV1, 41 and 63 is of particular importance as these 
types are the only genotypes that form the genera mu and nu (recently, HPV 204 was also 
classified as a mu papillomavirus (hpvcenter.se)). Other putative novel genotypes 
phylogenetically close to these HPV types (belonging to these genera) might also remain 
undetected. 
 
Currently, there are 205 different HPV types recognized. Attempts to degenerate FAP 
primers more, in order to amplify a broader number of HPV types, as well as multiplexing 
specific HPV primers in the PCR reaction, might improve HPV detection, but will at the 
same time reduce specificity in the reaction (e.g. human DNA binding).  
 
 
1.4.1.2 Unbiased approach: Whole genome amplification 
 
 
By performing whole genome amplification (WGA), all the DNA present in a sample will 
be amplified without requiring previous knowledge of the DNA sequence. There are 
different methods that have been developed for high-fidelity WGA. 
 
Initial PCR-based WGA techniques were based on the use of degenerate/semi-degenerate 
primers [75]  and primer extension PCR [76].  These techniques used Taq polymerase and 
consequently, limited the amplicon fragment length to 3 kb and introduced errors in the 
sequence due to the lack of the enzyme´s 3´- 5´ exonuclease activity. Furthermore, they 
exhibited incomplete genome coverage and amplification bias [75-77] and therefore, were 
substituted by non-PCR based methods. 
 
Multiple displacement amplification (MDA) is today a gold standard method for non-
PCR based amplification techniques. It was first developed for rolling circle amplification 
[78] where the reaction starts by annealing random hexamer primers to the DNA template 
and DNA synthesis is carried out at constant temperature (Figure 4).  
 
The DNA polymerase used in MDA originates from bacteriophage phi29 [79, 80] and has 
a 3´- 5´ proofreading activity, resulting in a low intrinsic error rate and about 1000-fold 
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less accumulation of mutations compared to PCR techniques using Taq DNA polymerase 
[81, 82]. Moreover, Phi29 possesses a strong strand displacement activity, being able to 
solve secondary structures as hair pin loops, thereby preventing slipping, stopping and 
dissociation of the polymerase during amplification. Average product length can be 
greater than 10 kb [83]. 
 
 
Figure 4:   Overview of the whole genome amplification with focus on double stranded DNA (A). 
Random hexamer primers bind to single stranded DNA and amplification starts (B, C). When the 
polymerase reaches a downstream primer, the strand is displaced and new primers can anneal to 
the displaced product (D). The end product is double stranded repeated copies of the DNA in the 
sample (E). Figure adapted from Rector et al., A sequence-independent strategy for detection and 
cloning of circular DNA virus genomes using multiply primed rolling-circle amplification, in 
Journal of Virology, 2004; 78:4993-8, with permission from American Society for Microbiology. 
 
 
MDA provides an effective and easy means of amplifying minimal quantities of DNA and 
is the least biased WGA method reported [83, 84]. However, there are also biases 
associated with this technology. Chimera formation, preferential amplification of circular 
single stranded DNA (ssDNA) and non-uniform amplification of linear genomes have 
been documented [85, 86]. 
 
The predominant mechanism for chimera formation is now elucidated [87]. More than 
85% of chimeras are due to inverted sequences occurring when strand displacement takes 
place in the reaction. 3´-termini can be displaced and might reanneal at randomly 
occurring complementary segments on nearby 5´-strands, resulting in the joining of two 
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sequences in inverted orientation with an intervening deletion. Bioinformatic analysis 
might be able to find these sequences and remove them for further analysis. 
 
MDA has not shown the ability to accurately estimate the amount of viral populations 
present [88], most probably due to the preferential amplification of particular genomic 
regions during initial MDA priming events [89, 90].  Several investigators have proposed 
that pooling several independent MDA reactions run on a single sample of template DNA 
minimizes representational bias in shotgun metagenome sequence libraries [91-96]. 
However, this assumption has not been thoroughly tested [97]. 
 
There is no reported method that overcomes all amplification bias in MDA products. 
Hence, the effective use of MDA in any application depends on the user´s needs. E.g.: if 
the user is only interested in ssDNA sequences, skipping the denaturation step in the 
amplification will completely bias the ssDNA amplification, as primers will not be able to 
bind to non-denatured dsDNA [98]. 
 
Even though MDA was traditionally used to amplify circular DNA [96], it can be used to 
amplify linear DNA [83, 100]. In Paper III, we quantified the amount of amplification of 
both human DNA and HPV DNA by adding 20 copies/μL of HPV 16 plasmid to samples 
of human placental DNA at 1 ng/μL. We amplified these samples in the same manner as 
for the clinical samples and quantified the amounts using real-time PCR for beta-globin 
and for HPV 16, respectively. Human DNA was found to be amplified 26-fold, whereas 
HPV 16 DNA was amplified 679-fold. Thus, although the WGA will have made it easier 
to detect the circular HPV genomes, it is unlikely that we would have missed linear and/or 
large dsDNA viruses unless they were present in only small amounts.  
 
 
1.4.2 Detection techniques 
 
 
Detection of amplified products is usually performed by hybridization of amplicons to 
type-specific probes coupled to fluorescent beads [101, 102] or by product sequencing 
[20, 21, 48, 103]. 
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1.4.2.1 Hybridization to type-specific probes 
 
 
Detection of amplicons using probes requires prior knowledge of the DNA sequence 
query in order to design specific probes. There is a large variety of molecular assays 
based on hybridization used for detection of different microorganisms [104, 105]. Some 
of the hybridization methods for HPV DNA typing include the Hybrid Capture II test 
(Digene Corporation, Gaithersburg, MD), the LINEAR ARRAY® HPV genotyping test 
(Roche Molecular Systems, Alameda, CA), the INNO LiPA® HPV genotyping test 
(Fujirebio, Gent, Belgium), and the Cervista® HPV (Hologic Inc., Marlborough, MA).  
 
Accurate and internationally comparable DNA detection and typing methodology is an 
essential component both for research and for diagnosis. The World Health Organization 
(WHO) started a WHO Global HPV Laboratory Network (LabNet) in 2006 to support the 
world-wide development and implementation of HPV vaccines through improved 
laboratory standardization and quality assurance of HPV testing and typing methods 
(Technical Report on the Global HPV LabNet 2013 HPV DNA Genotyping Proficiency 
Panel). The results show a yearly increase in proficiency (sensitivity and specificity) of 
HPV typing assays when routinely used in laboratories worldwide [106, 107]. 
 
Despite a high sensitivity and specificity of these methods, their major limitation is the 
potential for error in HPV typing because of probe cross-hybridization when cross-
reactivity of one probe to several target groups occurs (false positivity). Furthermore, 
sequences with low similarity to the probes or sequences that present small variations and 
point mutations might not be detected (false negativity). Therefore, these methods are not 
valid when searching for novel viruses and/or sequences. 
 
A recent study developed a comprehensive viral targeted sequence capture panel using 
hybridization probes, that were able to assess all viruses known to infect vertebrate cells 
(excluding human endogenous retroviruses), as well as to detect divergent viruses [72]. 
The main advantages of this design are: complete viral genomes targeting, detection of 
viruses that show up to 58% variation from the reference virus used to select capture 
probes and, the possibility to isolate the capture sequences in order to sequence them 
afterwards [72].    
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1.4.2.2 High throughput sequencing 
 
 
With the establishment of the high throughput sequencing (HTS) technology (also called 
next generation sequencing (NGS) or deep sequencing), there is no need to test specimens 
for predefined microorganisms by PCR. Sequencing the DNA will determine which 
organisms are present by analyzing the sequence data. Furthermore, the entire sequence is 
obtained and this enables, both discovering novel viruses as well as finding small 
variations and point mutations within the previously known viruses. 
 
 
1.5 HIGH THROUGHPUT SEQUENCING INSTRUMENTS 
 
 
During the past decade, there has been a dramatic evolution of next generation sequencing 
technologies: 454 GS (Roche), SOLiD (ABI), Ion Torrent (Life Technologies) and 
Genome Analyzer System (Illumina). 
 
These recent technological advances have revolutionized the study of genomics and 
molecular biology. NGS allows us to sequence DNA and RNA much more quickly and 
cheaply than the previously used Sanger sequencing. Using capillary electrophoresis-
based Sanger sequencing, the Human Genome Project took over 10 years and costed 
nearly $3 billion. Nowadays, sequencing a human genome can be done in a variety of 
bench-top NGS instruments in a couple of days and at very limited costs. 
 
In this thesis, we have used 2 different sequencing technologies. We started sequencing 
with 454 GS Junior (Roche) but after about a year, quicker, cheaper and deeper platforms 
came on the market such as the Genome Analyzer System from Illumina (MiSeq, HiSeq 
and NextSeq platforms). A comparison of some of the platforms´ specifications used in 
this thesis is shown in Table 3. 
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Method Sanger-CE 454 GS Junior MiSeq HiSeq NextSeq 
Year 1980’s 2000’s 2010’s 2010’s 2014 
Output <100 kb 35 Mb 1500 Mb 600 Gb 120 Gb 
Read length 500 bp 400 bp 300x2 bp* 100x2 bp* 150x2 bp* 
Run time 7 h 8 h 56 h 11 days 29 h 
$ per Mb 2400 31 0.5 0.05 0,45 
 
Table 3:   Next generation sequencing platforms and their specifications. *Pair-end sequencing. 
 
 
1.5.1 454 GS technology (Roche) 
 
 
The 454 Life Sciences (454; Branford, CT, USA; now Roche, Basel) sequencing platform 
(the 454 Sequencer) was the first next-generation technology to reach the market. It was 
first commercially introduced in 2004. It dramatically increased the volume of sequencing 
conducted by research groups and expanded the range of problems that can be addressed 
by the direct readouts of DNA sequence.  
 
It was the first technology to sequence and assemble bacterial genomes de novo [108] and 
the first non-Sanger technology to sequence an individual human [109]. Other notable 
studies conducted by 454 included work as diverse as uncovering the potential cause of 
the disappearance of the honeybee [110], revealing the complexity of rearrangements 
between individual human genomes [111], providing new approaches to understand 
infectious diseases [112] - such as the mechanism of resistance to the drug R207910 
in Mycobacterium tuberculosis [113] - and sequencing the first million base pairs of a 
Neanderthal [114-116]. 
 
The GS Junior (454) technology is based on emulsion-based amplification and 
pyrosequencing. Its workflow is comprised of three main steps: generation of a single-
stranded template DNA library, emulsion-based clonal amplification of the library, and 
pyrosequencing (Figure 5). 
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1.5.1.1 Generation of a template DNA library 
 
 
The DNA is isolated and fragmented by nebulization. DNA fragments are polished and 
end repaired to create 3’Adenine ends to allow TA ligation of multiplex identifiers 
(MIDs) adaptors. These adaptors are very important, as they both allow sample 
quantification, and permit the user to multiplex sequencing, as each DNA fragment can be 
ligated to a different MID. 
 
Once the adaptor is ligated, a size selection step is performed to get rid of adaptors that 
were not ligated to the DNA fragments and samples are purified. Before continuing to the 
next step, it is important to assess the library quality and quantity in order to obtain the 
optimal number of molecules of library DNA for emulsion PCR.  
 
 
1.5.1.2 Emulsion-based clonal amplification of the library 
 
 
Pools of DNA libraries with different MIDs are combined with capture beads and then 
amplified by emulsion PCR. The beads are captured by droplets of a PCR reaction 
mixture in oil emulsion, and PCR amplification occurs in each droplet. This results in 
each bead carrying ten million copies of a unique DNA template. 
 
The emulsion is then broken, the bead-attached DNAs are denatured and the beads are 
deposited into wells of a fibre-optic slide, the PicoTiterPlateTM, containing hundreds of 
thousands of wells, wide and deep enough to contain only one bead. 
 
 
1.5.1.3 Pyrosequencing 
 
 
Pyrosequencing is a method of DNA sequencing based on the "sequencing by synthesis" 
principle. It relies on the detection of pyrophosphate release on nucleotide incorporation. 
The desired DNA sequence can be determined by light emitted upon incorporation of the 
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next complementary nucleotide. Only one out of four of the possible A/T/C/G nucleotides 
are added and available at a time, thus only one letter can be incorporated on the single 
stranded template (which is the sequence to be determined) and light is emitted (once per 
nucleotide incorporation). The previous nucleotide letter is degraded before the next 
nucleotide letter is added for synthesis. The intensity of the light determines if there is 
more than one of these nucleotides in a row. This process is repeated with each of the four 
letters until the DNA sequence of the single stranded template is determined. 
 
 
Figure 5:   Schematic overview of high-throughput sequencing using 454 GS (Roche). Image 
reprinted from Mardis et al., The impact of next-generation sequencing technology on genetics, in 
Trends in Genetics, 2008; 24:133-41, with permission from Elsevier. 
 
 
1.5.2 Genome Analyzer System technology (Illumina) 
 
 
The Genome Analyzer System technology was first developed by Solexa Inc., which 
launched the first Genome Analyzer in 2006. This platform enabled scientists to sequence 
up to 1 Gb of data in a single run. In early 2007, Solexa was bought by Illumina Inc., and 
it now supports a broad range of applications. Agrigenomics, cancer, forensics, complex 
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diseases, drug development, and microbial genomics as well as reproductive and genetic 
health are the most common fields where this platform has been used. With the added 
depth of sequencing, it enables: the identification of low-abundance genomes or those 
exhibiting modest expression differences between samples, discovering all types of 
genetic variations (SNPs, rearrangements, copy number variants, insertions, and 
deletions) [117-119], characterization of new bacterial isolates [120-122] and/or new 
variants that cause diseases, profiling DNA methylation status across the entire genome 
[123-125], defining somatic variations in cancer [124], and characterizing complex RNA 
populations for new genes and transcript structures [126, 127], among other utilities. 
 
Illumina's sequencing technology is based on cluster generation and sequencing by 
synthesis, tracking the addition of labeled nucleotides as the DNA template is copied in a 
massively parallel fashion. Its workflow follows three main steps: generation of a single-
stranded template DNA library, cluster generation, and sequencing by synthesis (Figure 
6). 
 
 
1.5.2.1 Generation of a template DNA library 
 
 
The DNA sample is prepared into a “sequencing library” by using either an enzymatic 
fragmentation followed by adding unique adapter sequences (forward and reverse 
oligomucleotides) to the sample, or an engineered transposome that simultaneously 
fragments and tags ("tagment") input DNA in the process. 
 
After tagmentation (or fragmentation and adapters ligation), a limited-cycle PCR reaction 
uses these adapter sequences to amplify DNA fragments. This PCR reaction also adds 
index sequences on both ends of the DNA fragments, enabling dual-indexed sequencing 
of pooled libraries on any Illumina Sequencing System. 
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1.5.2.2 Cluster generation 
 
 
The sequencing libraries are denatured and attached to a lawn of single stranded 
oligonucleotides immobilized on a flow cell surface. These olignonucleotides correspond 
to the complementary sequences of the adapters ligated during the library preparation 
step. Subsequently, each end of every library molecule matches one of the two primers on 
the glass surface.  
 
Once the sequencing templates are attached, amplification in a bridge-fashion occurs. The 
free/distal end of the DNA template loops over to hybridize the complementary surface 
primer (oligonucleotide). A DNA polymerase copies the templates from the hybridized 
oligonucleotides forming dsDNA bridges, which are denatured and result in two single 
strands that serve as a new template, and will then loop over and hybridize again.  
 
Priming will continue as the distal end of a ligated fragment bends over to a 
complementary oligo on the surface of the flow cell. Repeated denaturation and extension 
will result in millions of surface-bound colonies, each of them containing approximately 
one million copies of each template (the cluster). 
 
 
1.5.2.3 Sequencing by synthesis 
 
 
The Illumina sequencing method uses fluorescently-tagged dNTPs containing a 
terminator which blocks further polymerization. During each sequencing cycle, all 4 
labelled nucleotides are added to compete for addition (thus, minimizing incorporation 
bias) to the DNA strand. Only one nucleotide can be incorporated based on the sequence 
of the template.  
 
The included base behaves as a terminator for the polymerization. After each cycle, the 
fluorescent dye is imaged to identify the nucleotide and the terminator is cleaved to allow 
the incorporation of the next base. This process is repeated until the DNA sequence of the 
single stranded template is determined. 
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Figure 6:   Schematic overview of high-throughput sequencing using Illumina technology. 
 
 
1.6 HIGH THROUGHPUT SEQUENCING DATA ANALYSIS 
 
 
As even just one sequencing run provides enormous amounts of data, analysis and 
interpretation are challenging.  
 
Sequencing analysis usually starts by performing quality checking [128] (Figure 7). 
Quality checking is an important and effective measure for determining the quality of 
sample libraries, and it also serves to indicate whether the sequencing succeeded or failed. 
Bases are checked according to their Phred quality scores [128]. Phred quality scores are 
logarithmically related to the base-calling error probabilities. For example, a Phred quality 
score of 10 corresponds to a base calling accuracy of 90% (10 errors per 100bp), while a 
quality score of 20 equals to a base calling accuracy of 99% (1 error per 100bp) [128]. 
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Specific quality filtering conditions can be adapted for different downstream analyses 
[129].  
 
To obtain a dataset that contains reads of interest, e.g. the virus-related reads for viral 
metagenomics, sequences that are not a target of the investigation (e.g. human and 
bacterial reads) need to be filtered out on the bioinformatics level (Figure 7). This will 
further speed up the downstream analysis and decrease the risk of mis- assemblies [129].  
 
NGS sequences from human samples subjected to WGA typically contain more than 60 
percent human-related sequences. Human- and bacteria-related reads are the most 
commonly obtained reads, followed by sequences classified as “other” and “unknown” 
[31, 130] (Table 4). Viral reads usually represent less than 0.5% of sequencing data and 
enrichment for viral particles by ultracentrifugation has not been shown to be helpful in 
the analysis of biopsies or skin swabs [130].  
 
Negative control samples (PCR grade water) might also contain bacterial sequences and 
sequences classified as “other” and “unknown” [130]. Water controls have so far been 
found to be uniformly negative for viral sequences [130].  
 
These background sequences might be present due to the background reactivity of the 
Phi29 polymerase reaction [131] or represent environmental contamination and therefore, 
it is imperative that all metagenomic sequencing projects include sequencing of negative 
control samples [130].  
 
Once human and bacterial sequences are filtered out, data normalization is performed in 
order to decrease sample variation and discard redundant data such as duplicated reads 
(Figure 7). NGS technologies can produce duplicated reads due to errors in PCR 
amplification and/or sequencing [132, 133] and these reads might introduce an 
overestimation of the species abundance. Duplicated reads may also include natural 
duplicates that by chance originate from the same genomic position [132, 133]. Highly 
abundant species have a higher chance of natural duplicates [133] and their removal 
might introduce bias towards underestimation of abundances [132]. 
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Raw NGS Sequence Data 
 
 
Check Base Calling Accuracy 
(Phred quality scores – manual cut off) 
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Figure 7:   Bioinformatics pipeline to analyze high-throughput sequencing data for viral 
metagenomics. 
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  FFPE Biopsies Biopsies Skin swabs Water 
Sequencing platform GSFLX GSFLX GSFLX PGM 400  GSFLX 
Human 37,3 99,8 69,1 76,3 2,8 
Bacteria 21,3 0,1 24,2 18,3 52,2 
Virus 0,2 0 0,3 0,3 0 
Other 10,2 0 2,2 1 15,5 
Unknown 30,9 0 4,2 4,1 29,5 
 
Table 4:   Typical taxonomic assignment of NGS reads (%). Summary of results in previous 
studies, using different types of biospecimens, pre-treatments and NGS platforms. FFPE: Formalin 
Fixed Paraffin Embedded. Adapted from Bzhalava et al., Unbiased approach for virus detection in 
skin lesions, in PloS One, 2013; 8:e65953, with permission from the Creative Commons 
Attribution License.  
 
 
Sequence datasets are usually normalized using a digital normalization algorithm 
(http://ged.msu.edu/papers/2012-diginorm), which substantially reduces data size and 
computational resources for de novo assembly. NGS technologies produce billions of 
short reads from random locations in the genome by oversampling it and assembling 
those reads is the next step performed in the bioinformatics analysis (Figure 7).  
 
Assembly algorithms, in a process called de novo assembly, reconstruct original genomes 
which are present in the sample by merging short genomic fragments into longer 
contiguous sequences (“contigs”). There are two main types of de novo assembly 
programs: Overlap/Layout/Consensus assemblers, most widely applied to the longer 
reads and de Bruijn Graph assemblers, applied to the shorter reads. To validate assembly 
results, several assembly algorithms might be used, as well as re-mapping all singletons 
reads to assembled contigs [31, 134]. 
 
The possibility always exists that assembly algorithms may construct erroneous 
“chimeric” sequences by assembling sequences from different organisms or species. This 
problem may be particularly relevant for viral metagenomics where the biospecimens 
may contain a multitude of related viral sequences. For HPVs, we developed an algorithm 
to identify possible “chimeric” HPV sequences [135]. It is based on the assumption that 
an HPV genome should have similar degree of identity to the most closely related HPV 
type over its entire genome. Thus, HPV related sequences that have different degrees of 
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similarity over their length to the most closely related HPV sequence in GenBank are 
considered as possible chimeras (i.e. it is assumed that they contain parts of different 
HPVs). The algorithm checks these chimeras by dividing the sequence into three equal 
segments. If at least one of the segments has less than 90% similarity, another segment 
has more than 90% similarity and the difference between these segments is more than 5% 
(e.g. if segment 1 is 88% similar and segment 2 is 94% similar) the sequence is 
considered as “possibly chimeric”. This approach has been extremely valuable when 
analyzing HPV genotypes, however, it cannot be used for viruses that frequently 
rearrange parts of genomes with each other (e.g. Anelloviruses) and other algorithms must 
be developed [130]. 
 
Taxonomic classification of metagenomic reads can be performed by similarity and/or 
non-similarity-based methods. One of the most famous similarity-based taxonomic 
classifications is performed by NCBI BLAST, where sequences are compared to known 
genomes. However, a large part of the sequencing reads from de novo sequencing projects 
are classified as unknown [31, 130] due to incompleteness of public sequence databases or 
drawbacks of NGS technologies such as short read lengths and sequencing errors. 
Therefore, more sensitive algorithms, such as BLASTx and tBLASTx searches are 
conducted against protein databases after the BLASTn search on the nucleotide level. An 
example of this, would be to subject assembled contigs to taxonomic classification by 
comparing them against GenBank nucleotide database using paracel blast 
(www.strikingdevelopment.com) BLASTn to classify them as a) previously known 
sequences, b) related to previously known sequences, or c) unrelated to previously known 
sequences. 
 
One of the biggest challenges for bioinformatics analysis is the taxonomic classification of 
NGS data as many of the sequences, especially those belonging to viruses, have no 
homologs in the public databases or these homologs are highly divergent [136]. In 
BLAST searches, sequences might have multiple matches and to classify these sequences, 
several methods have been developed. One of the most frequently used is called MEGA 
[137]. This method finds the ‘Lowest Common Ancestor’ node of all matching sequences 
in the phylogenetic tree, reducing the risk of false positive matches. However, MEGA 
might produce false negative results by discarding sequences that do not satisfy user-
defined cut-offs.  
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In metagenomic samples, genome size is related to the number of reads and thus, 
MEGAN is suboptimal for quantitative metagenomic analyses. Nevertheless, other tools 
have been developed to address this issue. The GAAS (Genome relative Abundance and 
Average Size) tool [138] iteratively weighs each reference genome for all matching reads 
and normalizes the number of reads to the length of their genomes. GRAMMy (Genome 
Relative Abundance estimates based on Mixture Model theory) are another useful tool 
that models read assignment ambiguities, genome size biases and read distributions along 
the genomes on a unified probabilistic framework [139]. Both tools estimate similarities 
from the alignment qualities of the reads to the reference genomes but not from the 
reference genomes directly. Thus, they are very valuable for divergent genomes, but they 
are suboptimal in case there are highly similar genomes in the reference databases. The 
Genome Abundance Similarity Correction (GASiC) considers reference genome 
similarities to correct the observed abundances estimated via read alignments [140]. 
 
 
1.7 SIGNIFICANCE OF THE STUDY 
 
 
 
The development of sequencing technologies that perform high throughput sequencing 
together with the possibility of performing an unbiased approach, allows for the accurate 
identification of all microorganisms that are present in large numbers of biological 
specimens.  
 
The experiments carried out in this thesis have analyzed viral DNA present in skin tumors 
and the findings have contributed significantly to the knowledge of HPV genotypes. Until 
2004, only 106 HPV types had been completely cloned, sequenced and given an official 
number at the International HPV Reference Center. However, during the last 10 years, 99 
new types have been recognized (http://www.hpvcenter.se, accessed on 2016-01-15) and 
the number of putative novel HPV types is continuously growing. Our group has detected 
a total of 360 putative novel HPV types (called SE types) so far, all of them belonging to 
the genera alpha, beta and gamma (Figure 8) and one of them, HPV 197 (SE46) was 
found to be the most common genotype present in skin tumors. 
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The resulting “microbiological sequence atlas” obtained in this thesis can be used for 
large-scale molecular epidemiological analysis on whether any particular infection is 
regularly present in any specific form of skin cancer. Creating a solid and comprehensive 
basis for advancing knowledge in this area is important. Furthermore, if extensive 
sequencing efforts fail to find any infection present in cancer tissue, this would point to 
other hypotheses (e.g., a role of immunosurveillance in the recognition and elimination of 
precancerous lesions, regardless of cancer etiology, and in cancer cell gene expression) 
[15]. If properly carried out, therefore, also negative findings for viral sequences can 
provide useful clues about the origins of human skin cancer [16] .  
     31 
 
 
 
Figure 8:   Bayesian phylogenetic tree based on the L1 part of the complete 164 established 
HPV types (+ bovine papillomavirus type 3 and type 5) and 160 putative novel HPV types (SE-
types) that were >400 bp or contained >200 bp of the 3´-end of the amplimer. SE-types 
discovered using 454GSFLX and using Illumina MiSeq are presented in blue and red colors, 
respectively. 
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2 SUMMARY OF PUBLICATIONS  
 
 
 
2.1 AIMS 
 
 
The purpose of the studies included in this thesis, was to: 
 
 
Paper I: Next generation sequencing for HPV genotyping. 
 
Validate a high throughput sequencing method (454 GS technology, Roche) 
for PCR amplimers in order to detect and type HPV and compare it with the 
HPV genotyping method used by the WHO HPV LabNet global reference 
laboratory. 
 
 
Paper II: Diversity of HPV in skin lesions. 
 
Explore detection of cutaneous HPV genotypes in different skin lesions 
with optimized  chemistry and design of primers. 
 
 
Paper III: Deep sequencing extends the diversity of HPVs in human skin.  
 
Investigate the presence of additional viruses in skin lesions using a, 
compared to previous papers, deeper sequencing technology (Illumina 
technology). 
 
 
Paper IV: Human papillomvirus type 197 is commonly present in skin tumors. 
 
To explore which HPVs are most commonly detected in skin cancers when 
a sequencing method that is independent of PCR (not biased to any 
particular sequence) is used.  
 
 
Paper V: Does Human Papillomavirus-Negative Condylomata Exist? 
 
Analyze samples from “HPV-negative” condylomata with metagenomic 
sequencing to investigate which viruses these samples contain (if any).  
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2.2 MATERIALS AND METHODS 
 
 
2.2.1 Study material 
 
 
Paper I: Cervical, urethral and prostate specimens 
 
 
- Cervical samples: 
 
Cervical samples (n=62) were selected from Swedescreen, a population-
based randomized controlled trial of HPV DNA testing in primary cervical 
screening [141]. Specimens were collected through endo/ectocervical 
sampling with a cytobrush. The brush was swirled in 1 mL sterile 0.9% 
NaCl and samples were immediately frozen.  
 
- Urethral specimens: 
 
Urethral specimens (n=14) were selected from a university outpatient clinic 
in St. Petersburg. Samples were collected with a urinary swab that was first 
inserted into the urethra and rotated 180° right- and leftwards. The swab was 
rinsed in 1000 µl phosphate buffer and then stored at -20 °C.  
 
- Prostate samples: 
 
Prostate samples (n=11) were selected from the same university outpatient 
clinic in St. Petersburg. Specimens were collected after patients were asked 
to urinate and a digital rectal examination with massage of the prostate was 
done. The prostate secretion dropping from the urethra was stored at -20 °C.  
 
Frozen cervical, urethral and prostatic specimens were thawed and centrifuged. The 
pellet was dissolved and used for DNA extraction by a freeze-thaw-boiling procedure 
[142]. 
 
 
Paper II and III: Skin samples 
 
 
Two different patient series were used for both papers: 
 
- SCCs (n=119), AKs (n=114), BCCs (n=117), KAs (n=8), seborrheic keratosis 
(n=46) and two benign lesions (one prurigo nodularis and one benign 
hyperkeratoic skin lesion) were collected from a hospital-based study in Sweden 
and Austria. All patients provided four different samples: a swab sample and a 
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biopsy of the lesion as well as a swab sample and a biopsy from healthy skin. 
Swabs were collected by a pre-wetted (0.9% NaCl) cotton-tipped swab and 
biopsies were taken after tape-stripping the skin surface to remove possible 
environmental contamination. DNA biopsies were extracted using a phenol-free 
method [49] and with MagnNA Pure LC using the Total Nucleic Acid kit 
(Roche) whereas the swab samples were extracted by a freeze-thawing [49]. 
 
- Fresh frozen KA biopsies (n=92) were included in the study from the Department 
of Dermatology and Plastic surgery at the Norwegian National Hospital, Oslo, 
Norway. The DNA was extracted using the QIAmp DNA Minikit (Qiagen) [143]. 
 
 
Paper IV: Skin samples 
  
 
Two different patient series were used for this paper, formalin-fixed paraffin-
embedded blocks and fresh frozen biopsies: 
 
- Formalin-fixed paraffin-embedded (FFPE) SCC biopsies (n=24) were part of a 
larger study containing 130 SCCs, 378 BCCs and 157 other NMSCs at the 
Department of Pathology at Malmö University Hospital, Sweden. The paraffin 
blocks were sectioned, de-paraffinized using xylene and DNA was extracted by a 
phenol-free method [49]. 
 
- SCCs (n=17), AKs (n=22), BCCs (n=3), KAs (n=8) and SCCs in situ (n=17) 
were part of a Swedish hospital-based study of NMSCs, and premalignant and 
benign lesions. All patients donated 2 swab samples and 2 biopsies and DNA was 
extracted as described above. 
 
Paper V: Condyloma specimens 
 
 
Condyloma swab samples were collected from 703 patients visiting the Centre 
for Sexual Health in Malmö, Sweden between 2006 and 2009. Swab samples were 
collected with a pre-wetted (0.9% NaCl) cotton-tipped swab rolled over the 
condyloma and stored in 1 mL saline. Samples were then pelleted and cell suspension 
was DNA extracted with MagNA Pure LC using the Total Nucleic Acid Kit (Roche). 
In a previous study [144], the samples were subjected to MGP amplification followed 
by Luminex genotyping. Forty swab samples of apparently “HPV-negative” 
condylomata were included in this Paper. 
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2.2.2 Methods 
 
 
 
2.2.2.1 Sample adequacy 
 
Sample adequacy was assessed by amplification of the beta-globin gene with real-time 
PCR. 
 
 
 
2.2.2.2 HPV Amplification: 
 
HPV specific amplification 
 
 
In Paper I, two different sets of primers were used for HPV amplification: MGP and 
PGMY primers. Both general consensus primers amplify a region within the L1 gene (the 
MGP targeted region lies inside the region amplified by PGMY primers) and were 
designed to improve amplification of mucosal HPV types. 
 
MGP primers consist of five forward and five reverse primers which have a few modified 
nucleotides each compared to the general primers GP5+/6+ for better annealing to 
different HPV types [73]. The resulting HPV amplicon comprises approximately 160 bp. 
The PGMY primers PCR system is a set of 18 defined primers, which were designed to 
improve mucosal HPV type amplification of MY09/11 primers. These primers amplify a 
450 bp region within the L1 gene.  
 
While HPV genotyping using hybridization probes was carried out after MGP 
amplification of specimens (as we followed the same method and protocols that are 
validated and used at the WHO HPV LabNet global reference laboratory in Sweden), 
the 454 sequencing technology required a longer length of amplimers and thus, the HPV 
general PGMY primer set was chosen for viral amplification. PGMY primers and 
amplification protocols are also validated and included in the WHO Human 
Papillomavirus Laboratory Manual [145]. 
 
In Papers II, III and IV, another primer set was used, FAP59/64. These primers were 
designed to amplify most currently known cutaneous papillomavirus, and to generate an 
amplicon of about 480 nucleotides in the L1 ORF. The broad HPV amplification is due 
to the degeneration of primers instead of multiplexing. As FAP primers are normally 
used for skin samples, most of the FAP amplicons are usually expected to belong to 
beta and gamma genera. Some HPV types among alpha genus as well as those 
belonging to mu and nu genera might escape amplification due to mismatches with the 
primers (Table 5). Therefore, a new FAP6085/FAP64 primer system was designed in 
order to amplify and detect those “escaping” HPV types (Paper II). 
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FAP59 
HPV type Genus T A A C W G T I G G I C A Y C C W T A T T 
HPV 16 Alpha - T G - - - - - - - - - - - - - C - - - - 
HPV 5 Beta - - - - - - - - - - - - - - - - - - - - - 
HPV 50 Gamma - - - T - - - - - - - - - - - - - - - - - 
HPV 1 Mu - - - A - - - - A - - T G - - - - - T C - 
HPV 41 Nu - T - - - - - - - - - - - - - - - - T - - 
 
 
 
Table 5:   Alignment of the FAP59 and FAP64 primer sequences with the corresponding region in 
the L1 ORF of various HPV types. Lines and characters represent identical and mismatched 
nucleotides, respectively. Degenerate nucleotides of primers: W= T, A; I= inosine; Y= C, T; D= 
A, G, T; B= G, C, T. 
 
 
Long PCR amplification 
 
 
In Papers IV and V, complete genome sequences from putative novel types were detected 
by the sequencing platforms and long PCR amplification was performed to amplify these 
whole genomes in different overlapping fragments. The PrimeSTAR GXL DNA 
Polymerase kit from TAKARA was used for this purpose and individual PCR-programs 
were set for each fragment according to the manufacturer´s instructions. Specific primers 
were designed for each genome sequence. 
 
 
Unbiased approach: WGA 
 
In Papers III, IV and V, we attempted to perform an unbiased approach, not dependent on 
prior sequence information, and detect all DNA organisms present in skin samples by 
performing a whole genome amplification instead of a specific HPV PCR. DNA was 
amplified using the IllustraTM Ready-To-GoTM GenomiPhiTM DNA Amplification Kit 
(GE Health Care, United Kingdom) according to the manufacturer’s instructions, with 
some modifications. 
 
  
FAP64 
HPV type Genus G A T G G I G A I A T G D B W G A T A T W G G 
HPV 16 Alpha - - - - - - - - - - - - - - - C - - - C - - - 
HPV 5 Beta - - - - - - - - - - - - - - - - - C - - - - - 
HPV 50 Gamma - - - - - - - - - - - - - - - - - - - - - - - 
HPV 1 Mu - - - - - - - - - - - - - - G - - - - - - - - 
HPV 41 Nu - - - - C - - - - - - - - - - - - C - - - - - 
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Five microliters of sample were diluted with 20 L PCR-Grade water and 25 L of 
denaturation buffer. The mixture was incubated at 95°C for 3 min and then cooled on ice. 
For the amplification reaction, 50 L of the denatured samples were added to the Ready-
To-Go GenomiPhi lyophilized cake. Afterwards, samples were incubated at 30°C for 7 
hours and inactivated at 65°C for 10 min. Products were dissolved by diluting samples in 
the ratio 1:1 in PCR-Grade water or TE-buffer. 
 
 
 
 
2.2.2.3 HPV Detection 
 
 
Luminex system 
 
 
In Paper I, HPV was detected and genotyped using a multiplex bead-based hybridization 
method with Luminex, which is the HPV genotyping method used by the WHO HPV 
LabNet global reference laboratory. 
 
The system consists of type-specific probes bound to fluorescent beads and a 2-color laser 
which allows recognizing HPV types by detecting the fluorescence of streptavidin-F-
Phycoerythrin (identifying that hybridization occurred) and the color of the bead 
(identifying the HPV type). 
 
Beads with probes for 13 oncogenic (high-risk, HR-HPV) types (16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 68a and 68b) and 23 non-oncogenic types (6, 11, 26, 30, 40, 42, 43, 
53, 54, 61, 66, 67, 70, 73, 74, 81, 82, 83, 86, 87, 89, 90 and 91) were used. Furthermore, 
two “universal” probes were included in the study, aiming to represent other HPV types 
present in the specimens as well as those HPV types with point mutations that might not 
bind to their specific probes [146, 147].  
 
For Paper II, the Luminex assay was performed to screen more than 1000 skin samples 
for 44 putative novel HPV types. Unique probes were designed for each novel sequence 
and cross-reactivity was investigated. Probes were excluded if cross-reactivity was 
detected.  
 
 
Sequencing 
 
 
GS Junior technology was chosen as the sequencing platform for Papers I and II. 
However, new sequencing technologies with a deeper throughput came to the market and 
Papers III, IV, and V use protocols and sequencing data obtained with Illumina 
technology. A comparison of results from different sequencing technologies when 
sequencing the same samples can be seen in Paper III.  
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Real-time PCR 
 
 
In Paper IV, real-time PCR was used as a screening method to identify a putative novel 
HPV type (HPV 197) in all specimens included in the study. Specific primers and probes 
were designed and an HPV 197 plasmid was used as a positive control at different 
dilutions (from 100,000 to 0.5 copies/L). Real-time PCR was performed twice for each 
sample to confirm results and in case of ambiguity, real-time PCR was repeated a third 
time. 
 
 
2.2.2.4 New SE types and Cloning HPV types 
 
 
Nearly 100 sequences representing putatively novel HPV types (SE types) were detected 
in Papers II, III, IV and V. Usually, complete SE sequences of approximately 440 bp were 
obtained after sequencing FAP PCR amplimers. Each sequence was blasted against 
GenBank as well as against the rest of the “novel” HPV sequences found to avoid 
overestimation of “novel” HPV types. However, shorter sequences within the FAP region 
were also detected, most probably due to the DNA breakage or trimming in the 
bioinformatics step which removes low quality sequences. To avoid overestimation of 
putative new HPV types, phylogenetical analysis was restricted to sequences that were 
complete or almost complete fragments or contained >200 bp of the 5´-/ 3´-end of the 
amplimer, in order to eliminate the possibility that non-overlapping sequences might 
derive from the same virus. 
 
All these putative types with partial sequences were deposited in GenBank, but were not 
designated an official HPV type number as they were not cloned, submitted to the 
International HPV Reference Center, and completely sequenced. 
 
When performing WGA, a fragmentation step was performed when preparing the library 
for sequencing. Consequently, the HPV sequences obtained from one specimen might 
belong to different regions (E6, E2, L1, etc) and it could not be confirmed if non-
overlapping sequences belonged to the same HPV type (as multiple HPVs presence is 
common). To avoid overestimation of putative new HPV types, all “novel” sequences (SE 
types) that did not overlap but shared the same closest hit in BLAST, were considered to 
be the same SE type.  
 
In Papers IV and V, complete genome sequences were obtained for some novel HPV 
types (HPV 197, 200, 201 and 202) and these types were cloned. Long-PCR was 
performed as explained above and all fragments were gel-purified and cloned using the 
Zero Blunt VR TOPO VR PCR Cloning kit (Invitrogen) using the pCRTM-Blunt II-
TOPO VR vector. 
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2.2.2.5 Summary of methods throughout the papers  
 
 
Paper I: Next generation sequencing for HPV genotyping 
 
 
In order to validate and optimize a sequencing method for HPV detection, cervical, 
urethral, and prostate samples that had already been analyzed for HPV presence using 
Luminex technology (the HPV genotyping method used by the WHO LabNet global 
reference laboratory) were sequenced with the 454 technology (Roche) and the results 
were compared. 
 
Sensitivity of the sequencing method was investigated using a pool of plasmids (WHO 
HPV LabNet global proficiency panel) at different concentrations and reproducibility 
was assessed by preparing libraries and sequencing a group of specimens twice.  
 
 
Paper II: Diversity of HPVs in skin lesions 
 
 
After optimization and validation of the 454 method (Paper I), different pools of skin 
samples (total 326 specimens) were subjected to sequencing for HPV detection using 
the same technology, 454 Titanium Chemistry with GS Junior.  
 
A general set of degenerated HPV primers (FAP59/64) was chosen for amplification 
due to its higher specificity for HPV cutaneous types. Furthermore, a new set of primers 
(FAP6085/FAP64) was designed, validated with different plasmids, and tested in the 
same specimens in order to be able to amplify a broader number of cutaneous HPV 
types (alpha, mu and nu types), especially those where the FAP59/64 had mismatches.  
 
Unique probes were designed for 44 novel subgenomic sequences which had been 
detected in these skin pools in a previous study [33]. The Luminex assay was performed 
to investigate the prevalence of the sequences in various skin samples. 
 
 
Paper III: Deep sequencing extends the diversity of HPV in human skin 
 
 
The same FAP59/64 amplimer products used in Paper II together with a pool of whole-
genome amplified swab samples sequenced with GSFLX (Roche) and Ion Torrent PGM 
technologies in previous study [63] were sequenced using a deeper throughput 
technology, Illumina (MiSeq platform). 
 
Libraries for amplimers were prepared using the TruSeq Nano DNA Sample Preparation 
kit (Illumina), omitting fragmentation, end-repair, and size selection, as specimens 
consisted of approximately 450 bp long PCR products. Whole-genome amplified material 
was tagmented and sequenced following the Nextera DNA Sample Preparation kit. 
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Paper IV: HPV type 197 is commonly present in skin tumors 
 
 
In order to find all DNA organisms present in skin tumors and their prevalence, extracted 
DNA from fresh frozen biopsies and FFPE blocks from skin lesions were individually 
sequenced using both MiSeq and HiSeq instruments (Illumina) after whole genome 
amplification. A HPV consensus PCR (FAP 59/64) was also performed in order to 
compare the results of both types of amplification. 
 
A complete genome from a putative novel type (SE46) was detected in various specimens 
that had been amplified following whole genome amplification. Presence of this novel 
type was investigated using real-time PCR in all samples. The HPV genome was 
amplified, cloned and sequenced by Sanger sequencing to confirm the sequence. Clones 
were sent to the International HPV Reference Center (Karolinska Institutet, Sweden) that 
confirmed the DNA sequence and assigned the submitted clones the novel type number 
HPV 197. 
 
 
 
Paper V: Does Human Papillomavirus-Negative Condylomata Exist? 
 
 
Forty samples of MGP-PCR “HPV-negative” condylomas from a previous study [141] 
were whole genome amplified, tagmented, and individually sequenced using both MiSeq 
and NextSeq instruments (Illumina technology). Sequencing results from Illumina MiSeq 
were used to evaluate DNA library quality before sequencing them on Illumina 
NextSeq500 which provided about 2.7 Gb sequencing depth per sample with a read 
length of 150 bp paired-end. 
 
The complete genome sequences were obtained for 6 previously unknown HPV 
sequences, putatively representing new types. Three of them, were amplified and cloned 
from their respective specimens in two overlapping fragments each and sequenced by 
Sanger sequencing to confirm the sequences. Clones were sent to the International HPV 
Reference Center (Karolinska Institutet, Sweden) that confirmed the DNA sequences and 
assigned the submitted clones the novel type numbers HPV 200, HPV 201 and HPV 202. 
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2.3 RESULTS AND DISCUSSION 
 
 
2.3.1 Paper I 
 
 
NGS was evaluated as an HPV genotyping platform and compared to the HPV 
genotyping method used by the WHO HPV LabNet global reference laboratory. 
Sensitivity and reproducibility of the sequencing technology were also studied. 
 
The sensitivity analysis showed that GS Junior presented a higher sensitivity compared to 
Luminex. A pool of 15 different plasmids was used to perform this experiment and 13/15 
were detected at an input of 10 copies. Nevertheless, the numbers of reads detected were 
not correlated with the actual amount of virus present. This might be explained by the 
performance of the PCR protocol. All 15 plasmids were amplified as a pool, instead of 
performing individual PCRs and then pooling the amplicons. Amplifying a pool might 
translate into competition of HPV plasmids in order to bind to the primers. Those HPV 
types that bind better to the primer sequences would be more efficiently amplified and 
consequently may deplete PCR reagents than those HPV types that present mismatches 
with the primer sequence. The objective of pooling all plasmids at the same time instead 
of performing individual reactions was to reflect the situation found in real specimens, 
where multiple infections are common. Junior detected multiple infections with almost no 
limit in the number of types possible to detect in a sample (15 different types were 
detected in the sensitivity analysis). 
 
Most of the samples tested (72.7%) for reproducibility of the method showed perfect 
concordance for all types, even with multiple infections containing up to four types. 
Partial concordance was found in 6/33 samples, where genotypes with a low number of 
reads were not detected in one of the runs and three samples presented discordance (one 
genotype was detected with >50 reads in one run, but not in the other).  
 
GS Junior appeared to be an adequate and efficient tool for HPV genotyping. Sixty 
percent (36/60) of the samples tested with both genotyping methods showed perfect 
concordance. GS Junior detected more HPV types in 12 specimens (20%) while Luminex 
did in 8 (13.3%). 
 
Most genotypes that were not detected with the sequencing technology included HPV 
68a, 87, 90 and 91. As described in the Materials and Methods section, different primers 
were used for each method. When analyzing genome sequences of the genotypes not 
detected with GS Junior together with the primer sequences, PGMY primers presented 
many genotype binding mismatches (Table 6). Therefore, these genotypes might not have 
been efficiently amplified, especially in those cases where other genotypes that bind better 
to the primers were present in the same specimens. Broader or additional general primers 
would improve the sequencing method. 
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Overall, GS Junior presented three main advantages when comparing the results to those 
obtained from the HPV genotyping reference method (Luminex system). First, the 
sequence technology was able to detect all HPV types present in a sample while Luminex 
detected only those that were represented by specific hybridization probes. For example, 
HPV 32-positivity was detected in one specimen with the sequencing platform while 
Luminex considered it to be negative due to lack of a specific probe designed for this 
genotype. 
 
Secondly, mis-typing due to cross-reactivity was non-existent with the sequencing 
technology. One specimen was genotyped as HPV 114 with GS Junior while it was 
genotyped as a multiple infection of HPVs 83 and 86 with Luminex. These genotypes are 
phylogenetically related to HPV 114 and thus, a cross-reaction might have occurred as a 
specific probe for HPV 114 was not designed. 
 
Lastly, GS Junior enabled the user to obtain the entire sequence of the amplimer that 
might be useful to look for point mutations or variations for epidemiological studies and 
surveillance of HPV infection. 
 
 
 
HPV 90 G A C C A A T T C C C T C T T G G C A G 
PGMYF G A T C A G T T T C C T T T G G G A C G 
PGMYG G A T C A G T T T C C T T T A G G T C G 
PGMYH G A T C A G T T T C C T T T T G G A C G 
PGMYI G A T C A G T T T C C C C T T G G C 
  
PGMYJ G A T C A G T A T C C T T T G G G A C G 
PGMYK G A T C A G T A T C C C C T T G G A C G 
PGMYL G A T C A A T T C C C T T T A G G T C G 
PGMYM G A T C A A T T T C C A C T A G G T C G 
PGMYN G A T C A A T A T C C C C T T G G T C G 
PGMYP G A T C A G T T T C C G T T G G G C 
  
PGMYQ G A C C A G T T T C C C T T G G G T C G 
PGMYR G A C C A G T T T C C T T T A G G A C G 
 
Table 6:   HPV 90 and the reverse primers binding sequences. Highlighted nucleotides show 
mismatches with the HPV 90 genomic sequence. 
 
 
 
2.3.2 Paper II 
 
 
Roche sequencing platforms allowed for the possibility of performing bidirectional 
sequencing and the Titanium chemistry improved quality and read length of sequencing 
data. Both characteristics were assessed and used for sequencing FAP59/64 amplimers 
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from 326 skin samples in three different pools – fresh frozen biopsies from SCCs and 
AKs (A), fresh frozen biopsies from KAs (B) and swab samples from SCCs and AKs (C) 
- which had already been sequenced without both of the new technology advances [33]. 
 
It was speculated that the HPV general primer system FAP might have reached its limit in 
detecting new viruses [48], but our results showed the high effectiveness of pre-
amplication by general primer PCR followed by bidirectional sequencing. Overall, a total 
of 273 different HPV types or putative types were identified, 47 of those sequences 
belonging to novel putative types.  
 
The pool with swab samples contained most of the HPV sequences, being more 
frequently found those HPVs which belonged to genus gamma papillomavirus, followed 
by those in the genera beta papillomavirus and alpha papillomavirus. Presence of 
anogenital oncogenic HPV in skin samples has been reported [61, 148] and contamination 
of the skin by viruses originating from mucosal surfaces, mediated by the fingers has also 
been confirmed [149, 150]. Fresh frozen biopsies were taken after tape-stripping the skin 
surface [62], to reduce possible contaminating viruses, and only a single alpha 
papillomavirus (HPV 94) was found, suggesting that its presence might represent an 
infection. However, swab samples were collected without tape-stripping the skin, and 
therefore, higher presence of alpha papillomavirus was most probably due to 
contamination of the skin. 
 
HPVs from mu and nu genera were not detected. As the 3 genotypes (HPV 1, 41, and 63) 
included in these genera are distantly related to other HPV genera, novel primers were 
designed to detect those specific HPV types as well as to investigate whether the broad 
detection of HPV types could be further improved (alpha, beta and gamma genera). This 
novel combination of primers did not detect Mu- or Nu- papillomaviruses either. The 
FAP59/64 primer set detected 76 known HPV types, 117 previously known putative 
types, and 35 subgenomic sequences representing putatively novel types. Novel primers 
combination detected 33 known types, 45 previously known putative types, and 12 
subgenomic sequences representing putatively novel types. To avoid overestimation of 
putative new HPV types, phylogenetical analysis was restricted to those sequences that 
were complete or almost complete fragments or contained >200 bp of the 5-end of the 
amplimer (to discard the possibility that non-overlapping sequences might derive from the 
same virus) (Figure 9).  
 
The three pools were re-sequenced using 121 MIDs and altogether sequences from 283 
different known and putative HPV types were detected. In pool A, 93 HPV types/putative 
types were detected. 3 HPV types were detected by all MIDs while up to 20 
types/putative types were detected by more than 50% of the analysis. Re-sequencing pool 
B revealed the presence of 190 known and putative HPV types. Only 6 HPV types were 
detected by all MIDs and 59 types/putative types were detected by more than half of the 
re-sequencings. Pool C showed the presence of 174 HPV types (including known and 
putative types) of which 57 were detected by all MIDs and 90 were detected by more than 
50% of the analysis. 
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Figure 9:   Maximum likelihood tree based on 42 of the novel putative SE sequences identified in this 
study and L1 from representative known PV types from all other genera. All SE sequences belonged to 
gamma and beta genera. 
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A clear distinction was observed between those HPV types that were detected by all 
MIDs (and are probably present at high abundance) and those HPV types that were only 
picked by a few MIDs (and are therefore probably present at much lower copy numbers). 
High throughput sequencing was able to detect HPV types present in very low copy 
numbers that would probably otherwise have been missed in the cloning step.  
 
The same pools had been sequenced before in the same platform (without using 
bidirectional sequencing and Titanium chemistry) and 44 subgenomic sequences 
representing novel types were identified (SE types). With bidirectional sequencing and 
Titanium chemistry, most of those sequences were detected with a longer read-length 
(average of 170 bp longer). Obtaining longer sequences of SE types revealed that some of 
the previously reported subgenomic SE sequences belonged to the same virus (a total of 
37 subgenomic novel sequences instead of 44). Furthermore, most sequences which were 
considered as preliminary in the previous publication due to insertion/deletion errors 
leading to stop codons in L1, were detected with a higher quality and without containing 
premature stop codons in the gene.  
 
 
 
2.3.3 Paper III 
 
 
A deeper sequencing performed with Illumina platform (MiSeq) extended the diversity of 
HPVs found in human skin. The same pools used in Paper II (HPV consensus PCR of 
fresh frozen biopsies and top of the lesion swabs) were sequenced with MiSeq platform 
revealing a total of 159 known HPV types (52 established types and 107 known putative 
types) and 226 sequences of previously unknown putative novel types, all belonging to 
the gamma, beta, and alpha genera.  
 
Phylogenetic analysis was performed with 160/226 novel putative HPV types clustered 
together in the beta and gamma genera, including those HPV amplimers that contained 
>400 bp or >200 bp and the 3´-end (to avoid overestimation of novel putative types). Two 
new branches (probable new HPV species), one for gamma and one for beta were formed 
with 17 and 9 novel putative HPV types, respectively. However, confirmation by cloning 
is needed in order to know if these new branches do indeed represent new HPV species.  
 
Analysis results from either SCC or from KA frozen biopsies showed no specific 
association between specific HPV types with any particular skin disease. Most HPVs 
detected were present in the different skin lesions with about the same proportions in all 
pools and more than half of all HPV sequences detected were novel putative types. 
Swabbing the surface of the skin enables characterization of the diversity of the viruses 
present, but it is less informative for determining associations with skin diseases as the 
viruses that are shed from other places on the body might also be detectable in swabs of 
skin surfaces on rather distant sites on the body (e.g. alpha papillomaviruses).  
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Continuing improvements of the sequencing technology are likely to continue to reveal an 
extraordinary and expanding diversity of cutaneous HPVs. In contrast to cervical cancer, 
where HPV 16 and 18 are detected in most cancer cases, in skin lesions, the majority of 
HPV types found after FAP amplification were only present in one specimen.  
 
Sequencing whole genome amplified products of swab samples in the MiSeq platform 
(Illumina) identified about 100,000 reads comprising 21 known HPV types, 2 known 
putative types, and 3 novel putative HPV types (Table 6). This pool of samples had been 
sequenced before using two other technologies - GS FLX (Roche) and Personal Genome 
Machine® (PGM) Ion Torrent – and a 256-fold and 35-fold larger number of viral reads 
was obtained with Illumina technology, respectively.  
 
All HPV types detected with GS FLX and Ion Torrent platforms (14 types in total) were 
identified with Illumina technology, except for 3 of them that had appeared with a single 
read each during previous sequencing runs. Furthermore, a known putative type (SE46) 
that had been detected with only a partial sequence when using GS FLX and Ion Torrent 
platforms, was detected with an increased sequence depth of 220 times and its complete 
genomic sequence when using Illumina technology (Table 7). 
 
Increasing sensitivity and throughput may cause assembly algorithms to construct 
erroneous “chimeric” sequences by assembling two different sequences from different 
viruses. Genomic recombination has not been described yet for HPVs. However, multiple 
HPV infections are common and both naturally occurring genomic recombination and 
PCR-mediated recombination may mislead phylogenetic analysis. A more strict 
bioinformatics pipeline, which detects and removes putative chimeras, was developed for 
this study. Hence, some sequences reported in previous studies did not pass the chimera 
checking step in the data analysis pipeline and thus, were not included when constructing 
the phylogenetic tree.  
 
 
 
 
Table 7:   Number of reads for the HPV types detected in whole genome amplified skin swab 
samples (n=142) by different sequencing platforms. GSFLX (Roche), PGM (Ion Torrent), MiSeq 
(Illumina). 
 
 
 
 
GSFLX PGM 300 bp PGM 400 bp MiSeq 
Total reads 121752 912218 381017 23699142 
Total viral reads 380 2750 765 98535 
Total HPV reads 378 2744 762 98265 
Total established HPV types 5 10 5 21 
Total known putative HPV types 2 2 2 2 
Total novel putative HPV types 0 0 0 3 
SE46 reads 22 132 44 4881 
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Results from swab samples after PCR or WGA revealed that sequencing of amplimers 
was unquestionably more sensitive (352 vs 26 different HPVs detected, respectively). 
However, whole genome amplified HPV 16 used as a plasmid control was detectable 
when present at about 0.04 copies/cell, indicating a high sensitivity for WGA. 
Furthermore, at least 11 HPVs that were detected in the metagenomic sequencing, were 
not detected when sequencing HPV general primer PCR amplimers, implying that these 
viruses were not effectively amplified by the general primers used. 
 
 
 
2.3.4 Paper IV 
 
 
An unbiased approach (WGA amplification) using NGS was performed in 91 specimens 
with both MiSeq and HiSeq Illumina platforms. To date, most authors have performed 
NGS on pooled samples, making it difficult to determine if any specific HPV type is 
particularly common among different specimens. This was the first study that carried out 
NGS on individual skin lesions.  
 
MiSeq sequencing identified a total of 73M reads while a higher throughput was obtained 
with HiSeq technology (1,271M reads). Viral reads represented around 0.03% of the total 
sequences in both platforms and most of them (>90%) were related to HPV. The non-
HPV viruses that were detected with MiSeq and HiSeq belonged to Anelloviridae family 
(torque teno virus). 
 
Overall, HPV sequences were found in 47/91 specimens, representing four established 
HPV types (HPV 16, 22, 120 and 124), two previously known putative types (HPV 
isolate 915 F06002KN1 and SE46), and four previously unknown sequences putatively 
representing new types (SE361, SE364, SE365 and SE366). All HPV types and putative 
types detected belonged to the genera beta and gamma papillomavirus, except for HPV 
16 (alpha type). Presence of anogenital oncogenic types in skin cancers has been 
confirmed in previous studies [61, 148]. HPV 16-positive skin cancers are not common 
and most probably, infection or contamination of the skin by viruses originating from 
anogenital mucosal surfaces, mediated by the fingers, might be the cause of detection 
[149, 150]. 
 
The complete genome of SE46 isolate was cloned from the FFPE specimen with SCC and 
clones and complete genome sequence were sent to the International HPV Reference 
Center at Karolinska Institutet in Sweden, where it was re-sequenced and established as a 
new HPV type, HPV 197 (GenBank accession number KM085343). HPV 197 comprised 
7,278 bp and belonged to the gamma genus, but demonstrated only 75% similarity to the 
most closely related type (HPV 178). 
 
Most reads obtained from both platforms, belonged to the novel type HPV 197 (SE46 
isolate) which was found in 36/91 samples -22 samples were positive with HiSeq and 23 
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specimens with MiSeq- and the majority of the viral reads came from a single FFPE SCC 
specimen (17,000 reads and 505,000 for MiSeq and HiSeq, respectively). 
 
Real-time PCR confirmed the presence of HPV 197 in 31/36 samples that were HPV 197-
positive by sequencing as well as in three other samples (1 BCC and 2 SCCs) from which 
neither MiSeq or HiSeq had detected this novel HPV type. Full quantification of the 
number of copies/cell was not performed in the real-time PCR experiments. However, an 
HPV 197 plasmid at different concentrations was used as a positive control and all 
samples showed a concentration below 0.5 copies/cell, meaning that the detection of a 
high number of reads of HPV 197 (such as 17,000 or 505,000 reads with both MiSeq and 
HiSeq platforms in one FFPE specimen) was due to WGA amplification and not to an 
initial high amount of virus in that particular specimen. To confirm this conclusion, real-
time PCR was performed in amplified products and only the FFPE specimen that 
contained such a high number of reads showed a concentration above 0,5 copies/cell 
(>100,000 copies/cell). 
 
In accordance to our study, most authors have found HPV types in skin lesions only at 
very low viral loads (<1 copy/1,000 cells), but studies have not been consistent regarding 
which specific types are most commonly present (due to the different primers used) [22, 
64, 65].  With an unbiased approach we found that most skin tumor specimens contain 
HPV, with HPV type 197 being the most commonly detected virus. Nevertheless, further 
studies are needed to resolve the biological significance of this finding. 
 
For comparison, the same samples were individually amplified with FAP59/64 primers, 
pooled and sequenced with the MiSeq platform. A total of 24 established HPV types, 13 
previously known putative types and 3 novel putative types were detected, reflecting a 
higher sensitivity when sequencing PCR amplimers. However, only HPV 124 and 
putative novel type SE361 were detected both when sequencing without prior general 
primer PCR and when sequencing PCR amplicons.  
 
HPV 197, which was detected in 39.6% of samples when performing an unbiased 
approach, was not detected when carrying out FAP PCR. Analyzing FAP PCR primer 
target sequences confirmed several mismatches in HPV 197. PCR was more sensitive 
than the unbiased method, but it is dependent on a particular sequence. Thus, novel 
sequences and/or novel viruses might not be detected. More unbiased PCR-independent 
methods to describe which HPV types are most commonly present in skin lesions are 
needed. It is essential to first identify which known or unknown HPV types are present in 
the specimens, as studies looking for RNAs for only some of the viruses present might not 
be analyzing the major infection present. 
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2.3.5 Paper V 
 
 
With NextSeq platform, 700M reads were obtained, of which 363,182 were viral reads 
(0.05% of total sequences). Deeper sequencing enabled the detection of HPV in almost all 
condylomata. Ninety-one percent of viral reads were related to HPV sequences and they 
were present in 37/40 specimens (92.5%). All HPV-positive samples had more than 10 
HPV reads and based only on established HPV types, 31/40 samples were positive for 
multiple HPV types, with a maximum of 8 different established types.  
 
Sequencing of apparently HPV-negative specimens from diseases known to be HPV-
associated continues to identify a large number of previously unknown HPV sequences. 
HPV sequences represented a total of 75 different HPV types or putative types within the 
genera alpha, beta and gamma, out of which 43 represented novel putative HPV types.  
 
Six of the novel putative HPV types represented complete HPV genomes and three of 
them were cloned and established as HPV types 200, 201 and 202. They belonged to the 
genus gamma papillomavirus, but shared only 79%, 68% and 82% similarity to the most 
closely related type. 
 
HPV 6 and HPV 180 were the most frequent genotypes, detected in 30 and 18 samples, 
respectively. HPV 6 should have been detected by PCR in the previous study, as MGP 
primers are known to efficiently amplify this genotype [73]. Presence of viral variants 
with genomic substitutions in the sequences targeted by PCR primers or probes might 
explain this genotype amplification failure. Deep sequencing solved this problem by 
detecting HPV types without any prior sequence information. 
 
The rest of the virus related reads (9% of viral reads) belonged to Molluscum 
contagiosum virus (8% of total viral reads) and less than 1% of all viral reads were related 
to Baculoviridae, Herpesviridae, Microviridae, Mimiviridae, Parvoviridae, Iridoviridae 
and unclassified viruses. Interestingly, the Merkel cell polyomavirus, which is commonly 
present in healthy skin, was not detected.  
 
Molluscum contagiosum virus was detected in 24/40 samples and 22 out of those 24 also 
contained HPV sequences. This leaves only a single condyloma specimen where we 
found neither HPV, nor Molluscum.  
 
Presence of molluscum contagiosum virus is known to exist concomitantly with HPV 
[151]. Beta and gamma HPVs are frequently detected on healthy skin [32, 33, 135, 152] 
and therefore, presence of these types might be due to biological contamination from 
adjacent healthy genital skin. Clinical distinction between condyloma and mollusca is not 
always straightforward. Conceivably some of the condylomata might have been 
misdiagnosed and probably were mollusca rather than condylomata.  
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A previous study sequenced these 40 apparently HPV-negative condyloma specimens in 
pools of 4 samples with 454 pyrosequencing on a GS Junior instrument (Roche) [135]. 
HPV sequences were detected in half of the pools, detecting a total of 35 different HPV 
types (13 established HPV types, 1 known putative HPV sequence as well as 21 novel 
putative HPV sequences, all belonging to the gamma genus).  
 
As expected, more HPV types were detected with the deeper sequencing. It confirmed 
positivity (with a cutoff at >5 reads per sample) for 11 /13 established HPV types detected 
in the previous study and 13/21 novel putative HPVs. It also generated longer contigs of 
HPV sequences and thus, it confirmed that the 9 phylogenetically related but non-
overlapping fragments (SE92-100) did belong to the same novel HPV type (HPV 200) 
that was cloned and sequenced in the present study. Furthermore, another 3 putative novel 
types that had non-overlapping sequence fragments (SE106, SE107 and SE116) were all 
found to belong to HPV 201, also cloned and sequenced in the present study. 
 
 
 
2.4 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
 
The hypothesis that NMSC might be associated with an infectious agent derives mainly 
from the fact that immunosuppressed patients show a 100-fold increase in this type of 
cancer [18]. The first postulate designed by Robert Koch to establish a causative 
relationship between a microbe and a disease claimed that, “the microorganism should be 
found in abundance in all organisms suffering from the disease, but should not be found 
in healthy organisms”. Throughout this thesis, deep sequencing technology was applied in 
samples from skin lesions to find all possible DNA pathogens present (both known and 
previously unknown). At least 95% of detected viral reads were related to HPV. 
 
We used both PCR methods as well as an unbiased approach for HPV detection. PCR was 
more sensitive than the unbiased method, but it is dependent on a particular sequence. 
New degenerated primers were designed in order to amplify a broader number of HPVs, 
based on known sequences from HPV established types belonging to the 5 genera: alpha, 
beta, gamma, mu and nu. Overall, 56 more HPV types (established genotypes, previously 
known putative types, and sequences representing novel types) were detected with this 
novel set. However, viruses that were phylogenetically distant might still have escaped 
from PCR amplification. The characterized novel HPV 197 genotype (found in more than 
1/3 of specimens) for example, was only detected by an unbiased approach. Furthermore, 
more than 90% of condylomata that had been tested by PCR and were “apparently 
negative” for HPV, were positive for HPV DNA when the unbiased approach was used. 
 
We found almost 100 putative novel HPV types in total, and characterized 4 novel HPV 
types (HPV 197, 200, 201 and 202, Table 8). Most of the types were detected in very few 
patients each, and at a very low viral load (below 0.5 copies/μL). It might be debatable 
whether such low viral copy numbers are biologically relevant to tumor initiation and 
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maintenance. The role of these viruses does not seem to correspond to that of high-risk 
anogenital HPV, which commonly persist in high copy numbers in each tumor cell. HPVs 
found in skin could be due to contamination or carriage rather than the cause of a transient 
or persistent infection. The prevalence of HPV DNA in tape-stripped biopsies is far lower 
than that on the surface [62], further supporting a passenger role. Presumably, multiple 
positive samples of the same HPV type over a period of time would help to elucidate the 
role of this virus.  
 
In addition to the DNA presence, further studies on viral activity such as detection of 
HPV RNA (viral replication) or DNA integration would also facilitate the association of 
HPV with skin cancer. Contrary to cervical cancer, no signs of HPV integration have been 
observed in NMSC. Using in situ hybridization or RT-PCR to detect HPV mRNA in 
SCCs, have also failed to demonstrate activity of HPV so far, detecting viral transcripts 
sporadically at low levels in occasional tumors [153, 154], with many other tumors testing 
negative.  
 
Transcriptome sequencing emerged in 2013 and has been developing since, but HPV 
RNA expression in skin lesions has not been reported yet [155]. The latency period 
between primary infection and development of cancer is usually of 15 to 40 years [156], 
and thus, it is possible that an infection involved in carcinogenesis could have disappeared 
long before the cancer has developed. 
 
The genotypes found in healthy subjects are also mostly from the beta and gamma genera 
[32, 33, 135, 152]. This fact does not contradict Koch´s postulate, as it is known that most 
of the infections linked to human cancers are common in the whole human population, 
while only a proportion develops into cancer [156]. A synergistic function between 
persistent viral infections of the skin and ultraviolet exposure has been described [157-
159].  A study by Hall et al. showed that the combined effects of beta papillomavirus and 
presence of a susceptible phenotype like fair skin or prolonged sun exposure resulted in a 
greater risk of SCC than either risk factor alone [160]. 
 
Searching for infectious agents in human cancer is not an easy task. The work in this 
thesis has expanded our knowledge of the wide genomic diversity of HPV on the skin, 
and finds that more unbiased PCR-independent methods are needed to describe which 
organisms are most commonly present in skin lesions. Further studies to assess viral 
infections in cancer and elucidate the mechanistic effects are needed.  
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Table 8:   The 4 novel established HPV types (HPV 197, HPV 200, HPV 201 and HPV 202) 
genome organizations and their similarities of the open reading frames (ORFs) to the closest 
related HPV types. *Including STOP codon. 
 
HPV Total E6 E7 E1 E2 E4 L2 L1 
 
HPV 197 
(SE46) 
7278 444 285 1824 1179 477 1599 1548 Number of nucleotides* 
- 1-444 419-703 687-2510 2452-3630 2918-3394 3632-5230 5202-6749 Position of ORF in genome 
- 147 94 607 392 158 532 515 Number of amino acids (aa) 
- 61 (54) 67 (54) 75 (71) 74 (66) 75 (59) 70 (66) 75 (79) 
HPV178 Gamma-24 
% identity on nt level (aa level) 
HPV 200 
(SE370) 
7137 420 282 1797 1206 X 1509 1545 Number of nucleotides* 
- 1-420 417-698 685-2481 2408-3613 X 3613-5121 5132-6676 Position of ORF in genome 
- 140 94 599 402 X 503 515 Number of amino acids (aa) 
- 78 (72) 81 (84) 79 (80) 82 (79) X 77 (73) 79 (86) 
HPV48 Gamma-2 
% identity on nt level (aa level) 
HPV 201 
(SE371) 
7291 423 297 1827 1257 549 1554 1527 Number of nucleotides* 
- 1-423 420-716 700-2526 2468-3724 2934-3482 3726-5279 5289-6815 Position of ORF in genome 
- 141 99 609 419 183 518 509 Number of amino acids (aa) 
- 62(47) 64 (50) 66 (51) 67 (54) - 65 (55) 68 (68) 
HPV163 Gamma-20 
% identity on nt level (aa level) 
HPV 202 
(SE372) 
7344 432 300 1818 1179 369 1497 1587 Number of nucleotides* 
- 1-432 434-733 717-2534 2470-3648 3041-3409 3650-5146 5155-6741 Position of ORF in genome 
- 144 100 606 393 123 499 529 Number of amino acids (aa) 
- 87 (89) 86 (90) 87 (90) 88 (86) 90 (86) 77 (79) 82 (92) 
HPV140 Gamma-11 
% identity on nt level (aa level) 
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